Fate Therapeutics Inc

NASDAQ: FATE
$3.22
+$0.10 (+3.2%)
Closing Price on October 4, 2024

FATE Stock Chart and Intraday Price

FATE Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 768.10M USD
Shares Outstanding 99,238,000
Fate Therapeutics Inc is a pioneering biopharmaceutical firm based in San Diego, California, focusing on the creation of innovative cellular immunotherapies for cancer and immune disorders. The company is at the forefront of developing treatments using natural killer (NK) and T-cells, targeting conditions like multiple myeloma, lymphoma, autoimmune disorders, hematologic malignancies, and solid tumors. Through a strategic partnership with Ono Pharmaceutical Co. Ltd., Fate Therapeutics is advancing the development of off-the-shelf, iPSC-derived CAR T-cell therapies, aiming to revolutionize cancer treatment.

FATE Articles

Tuesday's top analyst upgrades and downgrades included American International Group, APA, Etsy, Goldman Sachs, Howmet Aerospace, Morgan Stanley, Wayfair, Welltower, Wendy’s and Workday .
Friday’s top analyst upgrades and downgrades included Analog Devices, Bath & Body Works, Cisco Systems, Elanco Animal Health, Exxon Mobil, Marvell Technology, MGIC Investment, Nvidia, Snowflake,...
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Cheniere Energy, Chewy, Costco Wholesale, CrowdStrike, Exact Sciences, Lululemon Athletica, New York Community Bancorp,...
Friday’s additional top analyst upgrades and downgrades were on BankUnited, Canadian National Railway, Fate Therapeutics, Moody's, Regions Financial, Snowflake, Travelers, Voya Financial and more.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Analog Devices, Applied Materials, Comcast, Chipotle Mexican Grill, Grab, IBM, Johnson & Johnson, Lyft,...
Tuesday afternoon's analyst upgrades and downgrades included Fate Therapeutics, Livent, RealReal, SmileDirectClub and more.
Thursday's top analyst upgrades and downgrades included Dick’s Sporting Goods, Fate Therapeutics, Kimberly-Clark, Nordstrom, Roblox, TJX Companies and Zoom Video Communications.
A couple of Cathie Wood's ARK Invest funds bought over 240,000 shares of Fate Therapeutics on August 3.
One of Cathie Wood's Ark Invest funds bought over 530,000 shares of Fate Therapeutics on July 7.
Monday's top analyst upgrades and downgrades included Capital One, Etsy, Fiserv, Progessive, Splunk, Ulta Beauty and Visa.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Alexion Pharma, Activision Blizzard, Baker Hughes, BioMarin, and more.
Friday's top analyst upgrades and downgrades included AIG, Best Buy, Carvana, Dell Technologies, HP, L Brands, Monster Beverage, Twitter and Zscaler.
Wedbush took a closer look at some of the companies in its coverage universe that are set to present at ASCO and what the impact may be going forward.
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.